The Advanced Glaucoma Intervention Study (AGIS): What Did It Teach Us About Long-Term Glaucoma Care?

Glaucoma is a chronic eye condition that requires lifelong monitoring and management. Because damage to the optic nerve is usually irreversible, long-term treatment strategies are essential to help preserve your vision and maintain your quality of life over time.

One of the most important studies in this field is the Advanced Glaucoma Intervention Study (AGIS). This landmark research project followed patients with advanced glaucoma that was inadequately controlled by medical treatment and compared two sequences of laser and surgical interventions over long-term follow-up.

If you are living with advanced glaucoma, studies like AGIS help your ophthalmologist understand which treatment strategies are most effective over extended periods.

The study provided valuable insight into how sustained reduction of intraocular pressure influences disease progression. It demonstrated that maintaining lower eye pressure over time is closely linked with better long-term outcomes for your vision. These findings continue to guide modern glaucoma management and surgical decision-making, especially in more advanced or complex cases.

By focusing on long-term outcomes rather than short-term improvements, AGIS helped reshape how ophthalmologists approach advanced glaucoma care. Today, its evidence supports more strategic, carefully monitored treatment plans designed to protect your vision for as long as possible.

What Was the AGIS?

The Advanced Glaucoma Intervention Study (AGIS) was a long-term clinical trial designed to compare different treatment strategies for patients with advanced open-angle glaucoma. If you are managing glaucoma, studies like AGIS help your ophthalmologist understand which approaches are most effective in maintaining long-term disease control.

Researchers aimed to determine which treatment strategies provided the most stable reduction in intraocular pressure and the best preservation of visual fields over time. This was important because sustained pressure control is closely linked to slowing glaucoma progression and protecting vision.

The study followed patients for many years, making it one of the most comprehensive glaucoma trials ever conducted. Its long-term design allowed researchers to evaluate outcomes over time rather than relying only on short-term improvements, providing valuable evidence that continues to influence modern glaucoma care and treatment planning.

Why Was the Study Important?

Before the Advanced Glaucoma Intervention Study (AGIS), there was limited clear evidence on how different sequences of treatment affected long-term outcomes in advanced glaucoma. If you had progressed glaucoma at that time, doctors often had to rely on clinical experience rather than strong comparative data to decide the best order of treatment.

There was uncertainty about the best sequence of laser and surgical interventions for patients whose glaucoma remained inadequately controlled despite medical treatment. AGIS was designed to compare two defined intervention sequences beginning with either argon laser trabeculoplasty or trabeculectomy.

The AGIS was designed to address this gap by providing structured clinical comparisons of different treatment sequences. Its results offered valuable long-term evidence that helped guide more consistent, evidence-based decision-making in glaucoma management, improving how your ophthalmologist approaches advanced disease today.

Study Design

The Advanced Glaucoma Intervention Study (AGIS) was a large, multicentre, randomised clinical trial designed to compare different treatment strategies for people with advanced glaucoma. If you had advanced glaucoma and met the study criteria, you would have been randomly assigned to one of the treatment pathways so researchers could objectively evaluate long-term outcomes.

Participants followed different treatment sequences during the study. Some patients underwent laser therapy first and received glaucoma surgery only if further treatment became necessary, while others had surgery earlier in their treatment course. Researchers then monitored each participant over many years to assess how these different approaches affected eye pressure control, visual field preservation, and overall disease progression.

This study design allowed researchers to compare the long-term effectiveness of different treatment strategies using high-quality clinical evidence. The findings continue to help your ophthalmologist decide the most appropriate treatment pathway based on the severity of your glaucoma, your response to previous treatments, and your individual clinical needs.

AGIS Treatment Sequences at a Glance

Treatment Pathway	First Intervention	Later Interventions If Needed	Main Purpose of Comparison
Laser-first sequence	Argon laser trabeculoplasty	Trabeculectomy could follow if additional pressure reduction was required	To examine the long-term outcomes of beginning intervention with laser treatment
Surgery-first sequence	Trabeculectomy	Further laser or surgical intervention could follow according to the study pathway	To examine the long-term outcomes of introducing filtering surgery earlier
Long-term follow-up	Regular eye pressure and visual field assessment	Further treatment according to response and study protocol	To assess pressure control, visual field change and long-term treatment outcomes

AGIS compared specific historical intervention sequences rather than every glaucoma treatment available today. Its findings are therefore most useful for understanding long-term pressure control and treatment planning principles rather than providing a fixed treatment order for every patient.

Who Took Part?

The Advanced Glaucoma Intervention Study (AGIS) included patients with advanced primary open-angle glaucoma who required significant reduction of their intraocular pressure to help protect their remaining vision. If you have advanced glaucoma, these are the types of patients whose outcomes helped shape the study’s conclusions.

Before entering the trial, participants underwent comprehensive eye examinations to assess the severity of their glaucoma and establish a baseline for future comparisons. Throughout the study, they attended regular follow-up appointments that included intraocular pressure measurements, visual field testing, and detailed optic nerve assessments to monitor the progression of the disease.

Long-term follow-up was a key strength of the AGIS, allowing researchers to evaluate how different treatment strategies affected glaucoma over many years. The information gathered continues to guide your ophthalmologist in selecting the most appropriate long-term management plan to help preserve your vision and slow disease progression.

Modern Glaucoma Medications

Today’s glaucoma medications are generally more effective and better tolerated than many of the treatments available during the Advanced Glaucoma Intervention Study (AGIS) era. If you have glaucoma, your ophthalmologist can choose from several different classes of pressure-lowering eye drops to develop a treatment plan that best suits your individual needs.

You now have access to multiple drug classes that work in different ways to reduce intraocular pressure. These medications can often be used in combination to achieve better pressure control when a single treatment is not sufficient. This flexible approach allows your ophthalmologist to tailor your therapy based on your eye pressure, the severity of your glaucoma, your response to treatment, and any potential side effects.

Although surgical techniques have continued to advance, medical therapy remains the first line of treatment for many patients with glaucoma. Regular use of your prescribed medication, together with ongoing follow-up appointments, plays a vital role in maintaining stable eye pressure and helping to protect your long-term vision.

Focus on Intraocular Pressure Control

A key objective of the Advanced Glaucoma Intervention Study (AGIS) was to understand how maintaining a sustained reduction in intraocular pressure affected the long-term progression of advanced glaucoma. If you have glaucoma, keeping your eye pressure consistently under control is one of the most important ways to help protect your vision.

AGIS analyses found that eyes maintaining lower IOP over repeated follow-up visits tended to experience less visual field deterioration. Later analysis of AGIS data also suggested that long-term IOP fluctuation may be associated with progression in some patients, particularly when mean IOP is relatively low. Together, these findings support careful long-term pressure control while recognising that the significance of pressure variation may differ between patients.

The AGIS reinforced the importance of maintaining a target eye pressure through ongoing treatment and regular follow-up. Today, your ophthalmologist will monitor your eye pressure closely and adjust your treatment when necessary to help keep it within a range that offers the best possible protection for your optic nerve and long-term vision.

Key Findings of AGIS

One of the most important findings of the Advanced Glaucoma Intervention Study (AGIS) was that patients who maintained lower intraocular pressure over the long term experienced less visual field deterioration than those whose eye pressure was less consistently controlled. If you have advanced glaucoma, these results highlight the importance of achieving and maintaining stable eye pressure to help protect your remaining vision.

The study also demonstrated that successful glaucoma management depends not only on the initial treatment you receive but also on how well your intraocular pressure is controlled over many years. Ongoing monitoring, regular follow-up appointments, and timely adjustments to your treatment plan are essential for reducing the risk of further optic nerve damage.

These findings helped define the goals of modern glaucoma care. Today, your ophthalmologist aims not only to lower your eye pressure but also to keep it consistently within your target range, helping to slow disease progression and preserve your vision for as long as possible.

Evidence Note: What Did AGIS Show About Eye Pressure?

One of the most influential analyses from AGIS examined the relationship between long-term intraocular pressure control and visual field deterioration.

In an analysis of 586 eyes, researchers grouped eyes according to how often their intraocular pressure was below 18 mmHg during six years of follow-up. Eyes that remained below 18 mmHg at every study visit had little average change in visual field defect score during follow-up. The average intraocular pressure in this group was approximately 12.3 mmHg.

For you as a patient, the important message is not that one pressure target is right for everyone. Instead, AGIS supports the principle that lower and consistently controlled pressure is associated with better visual field stability in advanced glaucoma. Your ophthalmologist will set an individual target based on the severity of your disease, previous progression and the pressure level needed to protect your remaining vision.

The Role of Surgery in Glaucoma Care

The Advanced Glaucoma Intervention Study (AGIS) provided important insights into the role of glaucoma surgery, particularly trabeculectomy, in managing advanced disease. If your glaucoma cannot be adequately controlled with medication or laser treatment, surgery may be recommended to lower your intraocular pressure and help protect your remaining vision.

The study showed that surgical outcomes could vary depending on the timing of the operation and the sequence of treatments used. These findings highlighted that successful glaucoma management is not only about choosing the right procedure but also about selecting the most appropriate treatment pathway for your individual condition.

Today, trabeculectomy remains one of the most effective surgical options for reducing eye pressure in patients with advanced glaucoma. Your ophthalmologist will consider factors such as the severity of your disease, your current eye pressure, your response to previous treatments, and your overall eye health before deciding whether surgery is the most suitable option for you.

UK Clinical Practice Note:
In current UK practice, advanced chronic open-angle glaucoma is treated differently from mild or moderate disease. NICE recommends offering glaucoma surgery with pharmacological augmentation, such as mitomycin-C where indicated, to people presenting with advanced chronic open-angle glaucoma. Alternative approaches may be considered when surgery is declined or unsuitable.

For you, this means that although AGIS remains historically important, modern decisions are not based on reproducing its ATT or TAT sequences exactly. Contemporary care uses newer medicines, selective laser trabeculoplasty, modern trabeculectomy techniques and other surgical options according to disease severity and your individual clinical needs.

Importance of Treatment Sequencing

One of the key lessons from the Advanced Glaucoma Intervention Study (AGIS) was that the order in which glaucoma treatments are given can influence long-term outcomes. If you have advanced glaucoma, the sequence of medication, laser treatment, and surgery may affect how well your intraocular pressure is controlled over time.

AGIS showed that treatment sequence could influence long-term outcomes, although the results were complex and did not support one universal pathway for every patient. Modern treatment decisions consider disease severity, likely target pressure, previous treatment response, surgical risk and individual circumstances. These findings demonstrated that choosing the right treatment at the right stage of your condition is an important part of successful glaucoma management, rather than simply selecting an individual procedure.

As a result, treatment planning became more strategic and personalised. Today, your ophthalmologist will consider the severity of your glaucoma, your response to previous treatments, and your overall eye health when deciding the most appropriate sequence of therapies, helping to achieve more stable pressure control and better long-term preservation of your vision.

Clinical Insight: AGIS Did Not Find One Universal Treatment Sequence

AGIS compared two defined intervention sequences after glaucoma had become inadequately controlled by medical therapy. One pathway started with argon laser trabeculoplasty before moving to trabeculectomy if needed, while the other started with trabeculectomy.

Long-term analyses showed that outcomes were complex and varied across the study populations. The results should therefore not be interpreted as proving that every patient with advanced glaucoma should follow exactly the same sequence.

For you, the modern lesson is that treatment escalation should be personalised. Your ophthalmologist will consider your remaining visual field, target pressure, previous treatment response, expected surgical benefit, risk of complications and other individual clinical factors before recommending the next step.

Visual Field Preservation

The Advanced Glaucoma Intervention Study (AGIS) placed strong emphasis on visual field outcomes because they reflect the functional vision that you use in everyday life. If glaucoma progresses, changes in your visual field can occur gradually, often before you become aware of any noticeable symptoms.

Researchers found that patients who maintained better long-term control of their intraocular pressure were more likely to preserve their visual fields over time. This demonstrated that consistent pressure management plays a vital role in slowing glaucoma progression and protecting your remaining vision.

The findings reinforced the importance of long-term disease monitoring. Regular visual field testing, together with optic nerve examinations and eye pressure measurements, allows your ophthalmologist to detect even subtle changes in your condition and adjust your treatment when necessary, helping to preserve your vision for as long as possible.

Individual Variation in Outcomes

The Advanced Glaucoma Intervention Study (AGIS) also highlighted that patients do not all respond to glaucoma treatment in the same way. If you have advanced glaucoma, your response to medication, laser therapy, or surgery may differ from that of another person with a similar diagnosis.

The study found that some individuals achieved excellent long-term control of their intraocular pressure and maintained stable vision for many years, while others experienced disease progression despite receiving appropriate treatment. This showed that glaucoma is a complex condition influenced by multiple factors, including the severity of the disease, individual biology, and response to treatment.

These findings reinforced the importance of personalised glaucoma care. Today, your ophthalmologist will regularly assess your eye pressure, optic nerve health, visual field results, and overall response to treatment, adjusting your management plan when needed to provide the best possible protection for your long-term vision.

Long-Term Monitoring Importance

Glaucoma is a lifelong condition that requires ongoing monitoring, even when treatment is working well. Regular follow-up helps your ophthalmologist detect progression early and adjust treatment when needed. Consistent long-term care is essential for protecting your vision.

• Eye Pressure Checks: Regular measurements help your ophthalmologist monitor whether intraocular pressure remains within the intended range.
• Optic Nerve Assessment: Examination of the optic nerve helps identify structural changes that may suggest disease progression.
• Visual Field Testing: Repeated visual field tests help detect changes in vision and show how glaucoma is affecting function over time.
• Treatment Adjustments: Ongoing follow-up allows medication, laser treatment, or surgical plans to be reviewed when your condition changes.

Overall, successful glaucoma management depends on both effective treatment and consistent long-term monitoring. Regular appointments help detect subtle changes before more vision is lost. This ongoing care supports better control of the condition and protection of your long-term sight.

Impact on Surgical Decision-Making

The Advanced Glaucoma Intervention Study (AGIS) significantly influenced how ophthalmologists decide when to recommend glaucoma surgery. If you have advanced glaucoma, the decision to proceed with surgery is now based on much more than your current eye pressure alone.

Rather than focusing solely on achieving short-term pressure reduction, your ophthalmologist will also consider your long-term pressure stability, the rate of glaucoma progression, the condition of your optic nerve, your visual field results, and your response to previous treatments. This broader approach helps determine whether surgery is the most appropriate option for preserving your vision.

The findings of the AGIS have helped make glaucoma treatment planning more strategic and individualised. By considering your overall risk of disease progression alongside your long-term treatment goals, your ophthalmologist can recommend the most suitable timing and type of intervention to provide the best possible protection for your remaining vision.

Advancements Since AGIS

Since the Advanced Glaucoma Intervention Study (AGIS) was conducted, glaucoma care has advanced considerably. If you are diagnosed with glaucoma today, you have access to a wider range of diagnostic tools and treatment options than were available when the study first began.

New surgical techniques, including minimally invasive glaucoma surgery (MIGS), have expanded the range of procedures that can help lower your intraocular pressure. In addition, advances in imaging technologies, such as optical coherence tomography (OCT), now allow your ophthalmologist to detect subtle changes in your optic nerve and retinal nerve fibre layer much earlier than before.

These innovations build on the principles established by the AGIS rather than replacing them. While modern technology has improved the way glaucoma is diagnosed and treated, the study’s central message remains the same: maintaining long-term control of your intraocular pressure and monitoring your condition closely are essential for slowing disease progression and preserving your vision.

Role of Minimally Invasive Surgery

Minimally invasive glaucoma surgery (MIGS) has changed the surgical landscape by providing additional treatment options for selected patients with glaucoma. If your eye pressure cannot be adequately controlled with medication alone, your ophthalmologist may consider a MIGS procedure as part of your personalised treatment plan.

These procedures are designed to lower intraocular pressure through smaller surgical approaches than traditional glaucoma operations. In many cases, they are associated with a lower risk of complications, less disruption to the eye, and a faster recovery, while still helping to improve the drainage of fluid from the eye.

MIGS is not suitable for every patient, particularly those with very advanced glaucoma who may require more substantial pressure reduction. Your ophthalmologist will assess factors such as the severity of your glaucoma, your target eye pressure, and your overall eye health before recommending the most appropriate surgical option. As research and technology continue to advance, surgical innovation is expanding the range of treatments available to help protect your long-term vision.

Clinical Context:

MIGS procedures can be useful for selected patients, but they should not automatically be viewed as replacements for trabeculectomy in advanced glaucoma. Patients with severe disease may require very low target pressures, and conventional filtering surgery remains important when substantial pressure reduction is needed. Modern studies of advanced glaucoma continue to support a major role for trabeculectomy in appropriately selected patients.

Importance of Personalised Treatment

The Advanced Glaucoma Intervention Study (AGIS) highlighted that glaucoma treatment should be tailored to each individual rather than following a one-size-fits-all approach. If you have glaucoma, the most appropriate treatment for you will depend on your specific clinical circumstances and how your condition changes over time.

Your ophthalmologist will consider several factors when developing your treatment plan, including the severity of your glaucoma, your intraocular pressure, your age, the condition of your optic nerve, your visual field results, and the rate at which your disease is progressing. These factors help determine the most suitable combination of medication, laser treatment, surgery, and ongoing monitoring for your needs.

This personalised approach improves long-term outcomes by ensuring that your treatment is appropriate for your level of risk and adjusted as necessary throughout your care. The lessons learned from the AGIS continue to support evidence-based, individualised glaucoma management aimed at preserving your vision and maintaining your quality of life over the long term.

Monitoring Technology Improvements

Modern imaging technologies have significantly improved the way glaucoma is monitored. If you have glaucoma, your ophthalmologist can now detect subtle structural changes in your eyes much earlier than was possible during the Advanced Glaucoma Intervention Study (AGIS).

One of the most important advances is optical coherence tomography (OCT), which produces highly detailed images of your optic nerve and retinal nerve fibre layer. These scans can identify early signs of glaucoma progression before noticeable changes appear in your vision or visual field tests, allowing treatment to be adjusted sooner when necessary.

Although these technologies were not widely available during the AGIS, they now play a major role in routine glaucoma care. Combined with regular eye pressure measurements and visual field testing, modern imaging has greatly improved disease tracking, helping your ophthalmologist monitor your condition more accurately and protect your long-term vision.

Influence on Global Guidelines

The findings from the Advanced Glaucoma Intervention Study (AGIS) have had a lasting influence on glaucoma management guidelines around the world. If you are receiving treatment for advanced glaucoma today, many aspects of your care are based on the evidence provided by this landmark clinical trial.

Clinicians continue to reference the AGIS when considering long-term treatment strategies, particularly the importance of maintaining consistent intraocular pressure control, preserving visual fields, and selecting the most appropriate sequence of treatments for each patient. The study also reinforced the value of regular follow-up and long-term monitoring in managing glaucoma effectively.

Although glaucoma diagnosis and treatment have advanced considerably since the AGIS was conducted, its key findings remain highly relevant. The study continues to serve as a cornerstone of evidence-based glaucoma care, helping your ophthalmologist develop a personalised treatment plan that aims to slow disease progression and preserve your vision for as long as possible.

Lasting Legacy of AGIS

More than two decades after it began, the Advanced Glaucoma Intervention Study (AGIS) remains one of the most important clinical trials ever conducted in glaucoma research. If you have advanced glaucoma today, many of the principles that guide your treatment are still based on the evidence generated by this landmark study.

The AGIS demonstrated that maintaining sustained control of your intraocular pressure, together with careful long-term monitoring, plays a critical role in slowing glaucoma progression and reducing the risk of permanent vision loss. It also showed that successful treatment depends on ongoing management rather than a single intervention.

Although glaucoma care has continued to evolve with new medications, advanced imaging, and minimally invasive surgical techniques, the core lessons of the AGIS remain highly relevant. Its influence continues to shape modern ophthalmology practice, supporting evidence-based, personalised care that helps your ophthalmologist protect your vision and maintain your eye health over the long term.

Seeking Specialist Glaucoma Care

If you have been diagnosed with glaucoma or have been identified as being at increased risk of developing the condition, seeking specialist ophthalmic care is essential. Early assessment, timely treatment, and regular follow-up provide the best opportunity to protect your vision and slow the progression of this lifelong eye disease.

Your ophthalmologist will monitor your intraocular pressure, examine your optic nerve, perform visual field testing, and use advanced imaging techniques when appropriate to assess how your glaucoma is changing over time. These regular assessments allow your treatment plan to be adjusted if necessary, helping to maintain stable eye pressure and reduce the risk of further vision loss.

The findings of the Advanced Glaucoma Intervention Study continue to support the importance of sustained pressure control, appropriate treatment escalation and long-term monitoring in advanced glaucoma. By attending routine appointments and following your ophthalmologist’s recommendations, you can help protect your remaining vision and support your long-term eye health.

Myth vs Fact

Myth	Fact
AGIS compared eye drops directly with surgery.	AGIS enrolled eyes with glaucoma inadequately controlled by medical treatment and compared two sequences of laser and surgical interventions.
AGIS proved everyone needs an IOP of 12 mmHg.	The 12.3 mmHg finding came from an observational subgroup analysis and should not be treated as a universal target.
One successful operation means glaucoma monitoring can stop.	Advanced glaucoma requires lifelong follow-up because treatment response and disease progression can change over time.
MIGS has replaced trabeculectomy for advanced glaucoma.	MIGS has expanded treatment options, but advanced disease may still require surgery capable of achieving very low target pressures.
Lowering IOP always stops glaucoma completely.	Lower pressure reduces progression risk, but some patients can still progress and need continued monitoring.
The same treatment sequence is best for every patient.	Treatment should be tailored to disease severity, progression rate, target pressure and individual circumstances.

Key Takeaways

• AGIS studied patients with medically uncontrolled advanced open-angle glaucoma.
• The study enrolled 591 patients and 789 eyes.
• It compared two intervention sequences beginning with either argon laser trabeculoplasty or trabeculectomy.
• Eyes maintaining lower IOP over repeated follow-up visits generally experienced less visual field deterioration.
• Eyes with IOP below 18 mmHg at every visit in one AGIS analysis had an average IOP of approximately 12.3 mmHg and little average visual field change.
• This finding should not be interpreted as establishing one universal target pressure for every glaucoma patient.
• Treatment-sequence findings were complex, supporting personalised rather than rigid treatment planning.
• Current UK practice for advanced chronic open-angle glaucoma may involve early glaucoma surgery rather than following the historic AGIS intervention sequences.
• Long-term monitoring remains essential even after successful pressure reduction.

FAQs:

1. What was the Advanced Glaucoma Intervention Study (AGIS)?
   The Advanced Glaucoma Intervention Study (AGIS) was a long-term clinical trial designed to compare different treatment strategies for advanced open-angle glaucoma. It focused on evaluating surgical and laser-based approaches over many years. The goal was to understand which methods best preserved vision and controlled eye pressure.
2. Why was the AGIS study carried out?
   AGIS was conducted because there was limited long-term evidence about the best sequence of laser and surgical interventions after glaucoma was no longer adequately controlled with medical therapy.
3. How was the AGIS study designed?
   AGIS was a multicentre, randomised clinical trial involving patients with advanced glaucoma. Participants were assigned to different treatment pathways, such as laser-first or surgery-first approaches. Researchers then followed them for many years to compare outcomes.
4. Who participated in the AGIS study?
   The study included patients diagnosed with advanced primary open-angle glaucoma requiring significant reduction in eye pressure. Participants underwent regular monitoring, including visual field testing and optic nerve assessments. Long-term follow-up was essential to track disease progression accurately.
5. What did AGIS reveal about eye pressure control?
   AGIS found that eyes with lower and more consistently controlled intraocular pressure tended to experience less visual field deterioration over long-term follow-up. This finding reinforced the importance of sustained pressure control in advanced glaucoma.
6. What were the key findings of AGIS?
   One of the major findings was that lower long-term IOP was associated with less visual field deterioration. The study also reinforced the importance of sustained pressure control and continued monitoring.
7. How did AGIS influence glaucoma surgery?
   AGIS provided valuable insights into procedures like trabeculectomy, a common glaucoma surgery. It showed that surgical outcomes can vary depending on timing and treatment sequence. Surgery remains an important option for advanced cases.
8. Why is treatment sequencing important in glaucoma?
   AGIS found that treatment-sequence outcomes were complex and varied across study populations. The modern lesson is that treatment escalation should be individualised rather than assuming that one fixed sequence is best for every patient.
9. How did AGIS impact long-term glaucoma care?
   AGIS reinforced that glaucoma requires lifelong monitoring and management. Regular checks of eye pressure, optic nerve health, and visual fields are essential. Ongoing care helps prevent irreversible vision loss.
10. What is the lasting legacy of the AGIS study?
    The AGIS study remains one of the most influential glaucoma trials in ophthalmology. It established the importance of sustained eye pressure control and long-term treatment planning. Its findings continue to shape global glaucoma management guidelines today.

Final Thoughts: What AGIS Still Teaches Us About Glaucoma Care Today

The Advanced Glaucoma Intervention Study (AGIS) remains one of the most influential pieces of research in modern ophthalmology, largely because it shifted the focus of glaucoma care towards long-term, sustained control of intraocular pressure. Rather than relying on short-term treatment success, it highlighted that preserving vision depends on consistent monitoring and carefully planned, long-term management strategies.

Even today, its findings continue to underpin clinical decision-making, from surgical sequencing to ongoing medical therapy. While treatments and technologies have advanced significantly since the study was conducted, the central message still holds true: glaucoma is a lifelong condition that requires proactive, individualised care to protect vision over time. If you’d like to find out whether glaucoma treatment in London is suitable for you, feel free to contact us at Eye Clinic London to arrange a consultation.

References:

1. Hung, S.-H., Yen, W.-T. and Lu, D.-W. (2025) ‘Advances in glaucoma diagnosis and treatment: integrating innovations for enhanced patient outcomes’, Biomedicines, 13(4), p. 850. Available at: https://www.mdpi.com/2227-9059/13/4/850
2. Filippopoulos et al. (2023) ‘Survival of visual function in patients with advanced glaucoma after standard guarded trabeculectomy with MMC’, Journal of Clinical Medicine, 12(4), p. 1639. Available at: https://www.mdpi.com/2077-0383/12/4/1639
3. King, A.J. et al. (2024) ‘Evaluating Primary Treatment for People with Advanced Glaucoma: Five-Year Results of the Treatment of Advanced Glaucoma Study’, Ophthalmology, 131(7), pp. 759–770. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11190021/
4. Ederer, F., Gaasterland, D.A., Dally, L.G., Kim, J., VanVeldhuisen, P.C., Blackwell, B., Prum, B., Shafranov, G., Allen, R.C. and Beck, A. (2004) ‘The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results’, Ophthalmology, 111(4), pp. 651–664. Available at: https://pubmed.ncbi.nlm.nih.gov/15051195/
5. AGIS Investigators (1998) ‘The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race: seven-year results’, Ophthalmology, 105(7), pp. 1146–1164. Available at: https://pubmed.ncbi.nlm.nih.gov/9663215/